Why triptan treatment can fail: Focus on gastrointestinal manifestations of migraine

Headache

Volumn 53, Issue SUPPL.1, 2013, Pages 11-16

  Newman, Lawrence C ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

5 hydroxytryptamine1B 1D agonist; gastroparesis; migraine; nausea; sumatriptan; triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ARTICLE; COMPARATIVE STUDY; DRUG TREATMENT FAILURE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; MIGRAINE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; TABLET; VOMITING;

GASTROINTESTINAL DISEASES; HUMANS; MIGRAINE DISORDERS; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 84878502961     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12111     Document Type: Article

References (27)

1. Loder E,. Triptan therapy in migraine. N Engl J Med. 2010; 363: 63-70.
2. Freitag FG,. Acute treatment of migraine and the role of the triptans. Curr Neurol Neurosci Rep. 2001; 1: 125-132.
3. Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D,. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007; 47: 1152-1168.
4. Tepper SJ, Spears RC,. Acute treatment of migraine. Neurol Clin. 2009; 27: 417-427.
5. Belvis R, Pagonabarraga J, Kulisevsky J,. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov. 2009; 4: 70-81.
6. 1B1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
7. Malik SN, Hopkins M, Young WB, Silberstein SD,. Acute migraine treatment: Patterns of use and satisfaction in a clinical population. Headache. 2006; 46: 773-780.
8. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C,. Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden. Headache. 2007; 47: 475-479.
9. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK,. Predictors of adherence to triptans: Factors of sustained vs lapsed users. Headache. 2009; 49: 386-394.
10. Panconesi A, Pavone E, Franchini M, et al. Triptans: Low utilization and high turnover in the general population. Cephalalgia. 2010; 30: 576-581.
11. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ,. Why headache treatment fails. Neurology. 2003; 60: 1064-1070.
12. Rapoport AM, Freitag F, Pearlman SH,. Innovative delivery systems for migraine: The clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010; 24: 929-940.
13. Silberstein SD,. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995; 35: 387-396.
14. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657.
15. Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed M,. Frequency and burden of headache-related nausea: Results from the American migraine prevalence and prevention (AMPP) study. Headache. 2013; 53: 93-103.
16. Diener HC, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: The sumatriptan naratriptan aggregate patient database. Neurology. 2004; 63: 520-524.
17. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B,. Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia. 2008; 28: 35-40.
18. National Headache Foundation. Migraine patient survey. 2010. http://www.headaches.org/files/presentations/2010-04-MigrainePatientSurvey.ppsx. Accessed 5 April 2013.
19. Valade D,. Early treatment of acute migraine: New evidence of benefits. Cephalalgia. 2009; 29 (Suppl. 3): 15-21.
20. Parkman H,. Migraine and gastroparesis from a gastroenterologist's perspective. Headache. 2013; 53 (Suppl. 1): 4-10.
21. Volans GN,. Migraine and drug absorption. Clin Pharmacokinet. 1978; 3: 313-318.
22. Tokola RA, Neuvonen PJ,. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984; 17: 67-75.
23. Tokola RA,. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia. 1988; 8: 139-147.
24. Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D,. Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. Headache. 2006; 46: 57-63.
25. Boyle R, Behan PO, Sutton JA,. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990; 30: 405-409.
26. Kaniecki RG,. Mixing sumatriptan: A prospective study of stratified care using multiple formulations. Headache. 2001; 41: 862-866.
27. Gruffydd-Jones K, Hood CA, Price DB,. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia. 1997; 17: 31-36.